G1 THERAPEUTICS INC. - COMMON STOCK
7.1500
17-September-24 14:59:58
15 minutes delayed
Stocks
0.0000
0.00%
Today's range
7.1400 - 7.1600
ISIN
N/A
Source
NASDAQ
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2022 22:41:26 By Nasdaq GlobeNewswire
-
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
23 Nov 2022 09:30:26 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Closing of Offering of Common Stock
22 Nov 2022 15:01:04 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Pricing of Offering of Common Stock
17 Nov 2022 19:12:26 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Proposed Public Offering of Common Stock
17 Nov 2022 15:01:05 By Nasdaq GlobeNewswire
-
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
02 Nov 2022 05:30:33 By Nasdaq GlobeNewswire
-
02 Nov 2022 05:28:23 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2022 16:40:30 By Nasdaq GlobeNewswire
-
26 Oct 2022 08:26:34 By Nasdaq GlobeNewswire
-
19 Oct 2022 11:30:57 By Nasdaq GlobeNewswire
-
10 Oct 2022 05:30:06 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 16:00:53 By Nasdaq GlobeNewswire
-
07 Sep 2022 07:00:29 By Nasdaq GlobeNewswire
-
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
06 Sep 2022 06:00:15 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2022 16:22:08 By Nasdaq GlobeNewswire
-
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
03 Aug 2022 05:30:32 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 16:15:05 By Nasdaq GlobeNewswire
-
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
25 Jul 2022 05:30:43 By Nasdaq GlobeNewswire
-
20 Jul 2022 08:00:31 By Nasdaq GlobeNewswire